Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when COCH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received second Nasdaq notice for failure to maintain $1.00 minimum bid price and has been granted a final extension until November 16, 2026 to regain compliance or face potential delisting.
Envoy Medical gets second Nasdaq extension until Nov 2026, plans reverse split if needed
Filed May 22, 2026 · Period ending May 19, 2026 · ~1 min read
Key Changes
-
high
Nasdaq granted Envoy Medical an additional 180 days (until November 16, 2026) to regain compliance with the $1.00 minimum bid price requirement after the company failed to meet the initial May 18, 2026 deadline.
Item 3.01 verify on EDGAR → -
high
Company has notified Nasdaq of its intention to execute a reverse stock split if necessary to meet the bid price requirement, which would reduce share count and increase per-share price proportionally.
Item 3.01 verify on EDGAR → -
medium
The extension was granted because Envoy meets all other Nasdaq Capital Market listing requirements including market value of publicly held shares; only the bid price remains deficient.
Item 3.01 verify on EDGAR → -
medium
Original deficiency notice was received November 19, 2025 after the stock traded below $1.00 for 30 consecutive business days, triggering the initial 180-day compliance period.
Item 3.01 verify on EDGAR → -
high
If Envoy fails to regain compliance by November 16, 2026, the stock faces potential delisting from Nasdaq, which could impact liquidity and investor access.
Item 3.01 verify on EDGAR →
Summary
Envoy Medical disclosed that it failed to meet Nasdaq's $1.00 minimum bid price requirement by the May 18, 2026 deadline, but received a second 180-day extension through November 16, 2026. The company originally fell out of compliance in November 2025 when its stock traded below $1.00 for 30 consecutive days.
This second extension represents the company's final opportunity to regain compliance before facing potential delisting. The company has informed Nasdaq it will implement a reverse stock split if necessary to meet the bid price requirement.
A reverse split would mechanically increase the per-share price by reducing the number of outstanding shares, though it wouldn't change the company's underlying market value or business fundamentals. Envoy remains compliant with all other Nasdaq listing requirements, including market value of publicly held shares. Retail investors should monitor whether the stock can naturally regain the $1.00 threshold or whether management proceeds with a reverse split. Watch for any announcement of the reverse split ratio and timing, as this will directly impact share count and could affect trading liquidity. The November deadline creates a clear timeline for resolution one way or another.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 19, 2026, the Company received a second staff notification from Nasdaq informing the Company that, although the Company had not met the Bid Price Requirement by the Compliance Date, the Company is eligible for an additional 180 day period, until November 16, 2026, to meet the Bid Price Requirement (the “Second Compliance Period”).
Envoy Medical failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the initial May 18, 2026 deadline. Nasdaq granted a second 180-day extension through November 16, 2026 based on the company meeting other listing requirements and its stated intention to effect a reverse stock split if necessary. If the company fails to meet the bid price requirement during this second compliance period, its stock faces potential delisting from Nasdaq.
Added in current filing · verify on EDGAR →
on November 19, 2025, Envoy Medical, Inc. (the “Company”), received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the “Common Stock”), had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market (the “Capital Market”) under Nasdaq Listing Rule 5550(a) (2) (the “Bid Price Requirement”) for the 30 consecutive business days prior to the date of the Notice.
The company originally received notice on November 19, 2025 that its stock had traded below $1.00 for 30 consecutive business days, triggering non-compliance with Nasdaq listing requirements. The company was given an initial 180-day period to regain compliance, which expired on May 18, 2026 without the stock achieving the required $1.00 minimum bid price for ten consecutive business days.
Added in current filing · verify on EDGAR →
Nasdaq’s determination that the Company is eligible for a Second Compliance Period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for listing on the Capital Market with the exception of the bid price requirement and the Company’s written notice to Nasdaq of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary.
Envoy Medical has notified Nasdaq of its intention to implement a reverse stock split if necessary to meet the $1.00 minimum bid price requirement. This corporate action would reduce the number of outstanding shares and proportionally increase the per-share price, though it does not change the company's underlying market capitalization or fundamentals.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify